Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 241

1.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.

Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P; Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators.

JAMA Oncol. 2017 Nov 22. doi: 10.1001/jamaoncol.2017.3695. [Epub ahead of print]

PMID:
29167892
2.

Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.

Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F; GISCAD investigators.

Eur J Cancer. 2017 Sep;83:106-115. doi: 10.1016/j.ejca.2017.06.029. Epub 2017 Jul 20.

PMID:
28735067
3.

Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.

Takayoshi K, Kusaba H, Uenomachi M, Mitsugi K, Makiyama C, Makiyama A, Uchino K, Shirakawa T, Shibata Y, Shinohara Y, Inadomi K, Tsuchihashi K, Arita S, Ariyama H, Esaki T, Akashi K, Baba E.

Cancer Chemother Pharmacol. 2017 Aug;80(2):333-342. doi: 10.1007/s00280-017-3371-0. Epub 2017 Jun 26.

PMID:
28653251
4.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C.

JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105.

5.

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.

Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM.

Br J Cancer. 2017 May 9;116(10):1271-1278. doi: 10.1038/bjc.2017.93. Epub 2017 Apr 11.

6.

Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial).

Kotake M, Aoyama T, Munemoto Y, Doden K, Kataoka M, Kobayashi K, Nishimura G, Fujita H, Nakamura K, Takehara A, Tanaka C, Sakamoto J, Nagata N, Oba K, Kondo K.

Oncol Lett. 2017 Feb;13(2):747-753. doi: 10.3892/ol.2016.5505. Epub 2016 Dec 14.

7.

Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer.

Yoon YS, Kim CW, Roh SA, Cho DH, Kim TW, Kim MB, Kim JC.

Anticancer Res. 2017 Mar;37(3):1297-1303.

PMID:
28314295
8.
9.

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.

Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR.

JAMA Oncol. 2017 Apr 1;3(4):472-480. doi: 10.1001/jamaoncol.2016.5469.

10.

Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).

de Baere T, Tselikas L, Boige V, Ducreux M, Malka D, Goéré D, Benahim E, Deschamps F.

Bull Cancer. 2017 May;104(5):402-406. doi: 10.1016/j.bulcan.2016.10.025. Epub 2016 Dec 16. Review.

PMID:
27993355
11.

A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study).

Hazama S, Maeda H, Iwamoto S, Kim HM, Takemoto H, Kobayashi K, Sakamoto J, Nagata N, Oba K, Mishima H.

Clin Colorectal Cancer. 2016 Dec;15(4):329-336. doi: 10.1016/j.clcc.2016.07.003. Epub 2016 Jul 18.

PMID:
27507128
12.

First-line cetuximab-based chemotherapies for patients with advanced or metastatic <i>KRAS</i> wild-type colorectal cancer.

Uemura M, Kim HM, Hata T, Sakata K, Okuyama M, Takemoto H, Fujii H, Fukuzaki T, Morita T, Hata T, Takemasa I, Satoh T, Mizushima T, Doki Y, Mori M; Multi-Center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO).

Mol Clin Oncol. 2016 Aug;5(2):375-379. Epub 2016 Jun 17.

13.

Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.

Pugh SA, Bowers M, Ball A, Falk S, Finch-Jones M, Valle JW, O'Reilly DA, Siriwardena AK, Hornbuckle J, Rees M, Rees C, Iveson T, Hickish T, Maishman T, Stanton L, Dixon E, Corkhill A, Radford M, Garden OJ, Cunningham D, Maughan TS, Bridgewater JA, Primrose JN.

Br J Cancer. 2016 Aug 9;115(4):420-4. doi: 10.1038/bjc.2016.208. Epub 2016 Jul 19.

14.

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB 3rd, Goldberg RM.

J Clin Oncol. 2016 Aug 10;34(23):2736-42. doi: 10.1200/JCO.2015.65.5092. Epub 2016 Jul 5.

15.

Is early response by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography a predictor of long-term outcome in patients with metastatic colorectal cancer?

Formiga MN, Fanelli MF, Dettino AL, Nicolau UR, Cavicchioli M, Lima EN, de Mello CA.

J Gastrointest Oncol. 2016 Jun;7(3):365-72. doi: 10.21037/jgo.2016.02.04.

16.

Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.

Sunakawa Y, Bekaii-Saab T, Stintzing S.

Cancer Treat Rev. 2016 Apr;45:97-104. doi: 10.1016/j.ctrv.2016.03.007. Epub 2016 Mar 14. Review.

PMID:
27002945
17.

Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX.

Lledo G, Huguet F, Chibaudel B, Di Fiore F, Mineur L, Galais MP, Artru P, Blondin V, Dupuis O, Abdiche MS, Jovenin N, Pozet A, Bonnetain F, Attia M, Dahan L, de Gramont A.

Eur J Cancer. 2016 Mar;56:115-21. doi: 10.1016/j.ejca.2015.12.020. Epub 2016 Feb 2.

PMID:
26845174
18.

DPYD Genotyping to Predict Adverse Events Following Treatment With Flourouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.

Boige V, Vincent M, Alexandre P, Tejpar S, Landolfi S, Le Malicot K, Greil R, Cuyle PJ, Yilmaz M, Faroux R, Matzdorff A, Salazar R, Lepage C, Taieb J, Laurent-Puig P.

JAMA Oncol. 2016 Jan 21. doi: 10.1001/jamaoncol.2015.5392. [Epub ahead of print]

PMID:
26794347
19.

Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis.

Kobayashi M, Endo S, Hamano Y, Imanishi M, Akutsu D, Sugaya A, Ochi D, Moriwaki T, Hyodo I.

Intern Med. 2016;55(2):127-30. doi: 10.2169/internalmedicine.55.5113. Epub 2016 Jan 15.

20.

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

Taieb J, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Lepage C, Emile JF, Laurent-Puig P.

JAMA Oncol. 2016 Jan 14:1-11. doi: 10.1001/jamaoncol.2015.5225. [Epub ahead of print]

PMID:
26768652

Supplemental Content

Loading ...
Support Center